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INTRODUCTION 
 
 Cardiovascular disease has emerged as a major health burden 
worldwide.1 Type 2 diabetes mellitus is an epidemic in India for the 
past few decades. Diabetes mellitus is the most important risk factor 
associated with two to four fold increased incidence of coronary artery 
disease.2   
Nearly 120 years have elapsed since serum uric acid was first 
described as risk factor for cardiovascular disease.3  Serum uric acid as 
a potential cardiovascular disease risk factor has ballooned in the last 
several years with numerous abstracts & research papers, multiple 
editorials & review articles. 
  
The four major risk factors for CAD viz, hypercholesterolemia, 
hypertension, diabetes mellitus, and cigarette smoking which were 
present in Framingham’s cohort are difficult to explain among Indians 
with CAD. CAD in Indians is present even with low cholesterol level.4 
Obesity, systemic hypertension, hypercholesterolemia is associated 
with Type 2 DM, as a result of insulin resistance state.5 
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Much but not all epidemiological research identifies 
hyperuricemia as a independent risk factor for the development of 
cardiovascular disease, renal disease & stroke, particularly in patients 
with hypertension or congestive heart failure and in women.6   
 
     Hyperuricemia has been found to be associated with obesity 
and insulin resistance, and consequently with type 2 diabetes.7  Further 
potentially important biological effects of uric acid relate to 
endothelial dysfunction by inducing antiproliferative effects on 
endothelium and impairing nitric oxide production and 
inflammation.8,9  Uric acid may play a role in immune activation with 
subsequent increased chemokine and cytokine expression.10,11  
           Puig et al has found that in patients with metabolic syndrome 
serum uric acid level was higher when compared with controls and 
that serum urate increases with the number of components of 
metabolic syndrome.12  In addition a recent study in rats showed that 
fructose – induced hyperuricemia plays a pathogenic role in the 
metabolic syndrome.13 
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Some have found a significant & specific independent 
association between uric acid level and cardiovascular mortality and 
morbidity, while others have come to an opposite conclusion.14 Thus 
despite abundant epidemiological evidence, the role of increased 
serum uric acid and cardiovascular risk is controversial.  
 
Here an attempt has been made to study the level of serum uric 
acid level in Type 2 diabetes mellitus & the correlation between 
elevated serum uric acid level and the component of metabolic 
syndrome like obesity, hypertension, dyslipidemia.   
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AIMS AND OBJECTIVES 
 
          1) To identify the level of uric acid in patients with type 2 
Diabetes mellitus.  
 
 2) To identify whether any association exist between age, sex, 
anthropometric measurements (BM1, WHR), hypertension, 
dyslipidemia & coronary artery disease with serum uric acid level. 
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REVIEW OF LITERATURE 
DIABETES MELLITUS 
 
 Diabetic Mellitus is a group of metabolic diseases characterized 
by hyperglycemia resulting from defects in Insulin secretion, insulin 
action or both.15 The chronic hyperglycemia of diabetes is associated 
with long term damage, dysfunction and failure of various organs, 
especially the eyes, kidneys, nerves, heart and blood vessels.16 
 
CLASSIFICATIONS: 
 In 1997, ADA issued new diagnostic and classification criteria; 
In 2003, modifications were made regarding the diagnosis of impaired 
fasting glucose.17 The classification of diabetes includes four clinical 
classes, 
( Type 1 Diabetes: Results from β-cell destruction, usually 
leading to absolute insulin deficiency. 
( Type 2 Diabetes: Results from a progressive insulin secretory 
defect on the background of insulin resistance. 
( Other specific types of diabetes due to other causes, eg.(i) 
genetic defects in β-cell functions, (ii) Diseases of exocrine 
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pancreas, (such as cystic fibrosis), (iii) Drug or chemical 
induced (such as in treatment of AIDS or after organ 
transplantation) 
( Gestational Diabetes Mellitus (GDM): Diabetes diagnosed 
during pregnancy. 
 
DIAGNOSIS OF DIABETES: 
RECOMMENDATIONS: 
1. The Fasting Plasma Glucose (FPG) test is the preferred test 
to diagnose diabetes in children and non pregnant adults. 
2. Use of the A1C for the diagnosis of diabetes is not 
recommended at this time.18 
 
Three ways to diagnose diabetes are available and each must be 
confirmed on a subsequent day unless equivocal symptoms of 
hyperglycemia are present. Although the 75 g. oral glucose tolerance 
test (OGTT) is more sensitive and modestly more specific than the 
FPG to diagnose diabetes, it is poorly reproducible and difficult to 
perform in practice. Because of ease of use, acceptability to patients, 
and lower cost, the FPG is the preferred diagnostic test.19 
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CRITERIA FOR THE DIAGNOSIS OF DIABETES 
1. FPG ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no 
caloric intake for atleast 8 hours. (or) 
2. Symptoms of Hyperglycemia and a casual plasma glucose ≥ 
200 mg/dl (11.1 mmol/l). Casual is defined as any time of 
day without regard to time since last meal. The classic 
symptoms of Hyperglycemia include polyuria, polydipsia 
and unexplained weight loss.  (or) 
3. 2 hours plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an 
OGTT. The test should be performed as described by the 
World Health Organization, using a glucose load containing 
the equivalent of 75 g anhydrous glucose load containing the 
equivalent of 75g. anhydrous glucose dissolved in water.17 
 
DIAGNOSIS OF PRE-DIABETES 
 Hyperglycemia not sufficient to meet the diagnostic criteria for 
diabetes is categorized as either Impaired Fasting Glucose or Impaired 
Glucose tolerance, depending on whether it is identified through the 
FPG or the OGTT. 
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IFG = FPG 100 mg/dl – 125 mg/dl 
IGT = 2 hr. plasma glucose 140 mg/dl – 199 mg/dl. 
 
 IFG and IGT has been officially termed “Pre-diabetes”. Both 
IGT and IFG are similarly associated with endovascular disease 
outcomes. Risks are higher when IGF and IFG coexist. Lifestyle 
interventions are highly effective in delaying or preventing the onset 
of diabetes in people with IGT and may reduce LVD and total 
mortality.20 
 
EPIDEMIOLOGY 
 The prevalence of diabetes is rapidly rising all over the globe at 
an alarming rate.21 Although there is an increase in the prevalence of 
type 1 diabetes also, the major driver of the epidemic is the type 2 
DM, which accounts for more than 90%.  
 
 India leads the world with largest number of diabetic subjects 
earning the dubious distinction of being termed the “diabetes capital 
of the world”.22 According to the Diabetes Atlas 2006 published by 
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the IDF, the number of people with diabetes in India currently around 
40.9 million is expected to rise to 69.9 million by 2025.23,24(Fig.1).  
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Fig.2 is a map of India showing the prevalence of type 2 DM 
reported in different regions of India. 
 
Fig. 2.  Recent population based studies showings the prevalence 
of type 2 diabetes in different parts of India. 
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A study conducted by WHO & ICMR in 5 states of India, 
representing each zone has shown that the highest prevalence of DM 
was in urban areas followed by peri-urban and rural areas.32 
 
 The increase in the prevalence of type 2 DM among Indians is 
attributed to both genetic and environmental factors. The so called 
“Asian Indian Phenotype” refers to certain unique clinical and 
biochemical abnormalities in Indians which include increased insulin 
resistance, greater abdominal obesity, lower adiponectin and higher 
high sensitive C-reactive protein levels.33,34,35 This phenotype makes 
Asian Indians more prone to diabetes and premature coronary artery 
disease. 
 
 However, the primary driver of the epidemic of diabetes is the 
rapid epidemiological transition associated with changes in dietary 
patterns (Fast food culture)36 and decreased physical activity 
(Sedentarinism),37 as evident from the higher prevalence of diabetes in 
the urban population.38 
 
 Even though the prevalence of microvascular complication of 
diabetes like retinopathy and nephropathy are comparatively lower in 
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Indians, the prevalence of premature coronary artery disease is much 
higher in Indians compared to other ethnic groups.38 
 
 The most disturbing trend is the shift in age of onset of diabetes 
to a younger age in recent years. Mohan et al  has recently developed 
the Indian Diabetes Risk Score (IDRS) using four simple variables 
namely, age, family history, regular exercise and waist circumference 
(Table).39 
 
 
Table. Indian Diabetes Risk Score (IDRS) 
 
Particulars Score 
Age (yr):  
< 35 (reference)  0 
35-49  20 
>50  30 
Abdominal obesity:  
Waist <80 cm (female), <90 (male) (reference)  0 
Waist > 80-89 cm (female), >90-99 cm (male)  10 
Waist >90 cm (female), >100 cm (male)  20 
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Physical activity:  
Vigorous exercise or strenuous (manual) labour at 
home/work 
0 
Mild to moderate exercise or mild to moderate physical 
activity at home/work 
20 
No exercise and sedentary activities at home/work 30 
Family history:  
No family history (reference)  0 
Either parent  10 
Both parents  20 
Minimum score  0 
Maximum score  100 
 
Interpretation:  
Score < 30 low risk, score 30-50 medium risk and score > 60 
high risk for type 2 diabetes and cardiovascular diseases. 
 
PATHOGENESIS: 
 Insulin resistance and abnormal insulin secretion are central to 
the development of type 2 DM. Although the primary defect is 
controversial, most studies support the view that insulin resistance 
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precedes an insulin secretory defect but that diabetes develops only 
when insulin secretion becomes inadequate.40 
 
 Type 2 DM has a strong genetic component. The concordance 
of Type 2 DM in identical twins is between 70 and 90%. Individuals 
with a parent with type 2 DM have an increased risk of diabetes; if 
both parents have type 2 DM, the risk approaches 40%. A recent study 
has found a strong association of type 2 diabetes mellitus with a 
variant of the transcription factor 7- like 2 gene in several 
populations.40  
 The disease is polygenic and multifactorial since in addition to 
genetic susceptibility, environmental factors (such as obesity, nutrition 
and physical activity) modulate the phenotype. 
 In the early stages of the disorder, glucose tolerance remains 
near normal, despite insulin resistance, because the pancreatic beta 
cells compensate by increasing insulin output. As the disorder 
progresses, the beta cells are unable to sustain the hyperinsulinemic 
state. IGT, characterized by elevations in postprandial glucose, then 
develops. A further decline in insulin secretion and an increase in 
hepatic glucose production lead to overt diabetes with fasting 
hyperglycemia. Ultimately, beta cell failure may ensue.40 
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COMPLICATIONS OF DIABETES MELLITUS40 
 
Acute Complications    Chronic Complications 
 
1. Diabetic Ketoacidosis  Microvascular Macrovascular 
2. Non-Ketotic hyperosmolar 1) Retinopathy 1) Coronary artery 
 coma    2) Neuropathy               disease 
3. Hypoglycemia   3) Nephropathy 2) Peripheral  
     vascular disease 
3) Cerebrovascular 
 disease 
 
Others 
1. Gastrointestinal – Gastroparesis, diarrhea. 
2. Genitourinary – Uropathy / Sexual dysfunction 
3. Dermatological – Acanthosis nigricans. 
    4.        Infections – Emphysematous pyelonephritis, Mucormycosis,  
                                     Candidiasis. 
  16
METABOLIC SYNDROME 
 
Metabolic syndrome is a combination of medical disorders that 
increase the risk of developing cardiovascular disease and diabetes.  
Metabolic syndrome is also known as syndrome X, insulin 
resistance syndrome, Reaven’s syndrome, and CHAOS (Australia).41 
 
HISTORY 
The term "metabolic syndrome" dates back to at least the late 
1950s, 
The Marseilles physician Dr. Jean Vague, in 1947, observed 
that upper body obesity appeared to predispose to diabetes, 
atherosclerosis, gout and calculi.42 
In 1977, Haller used the term "metabolic syndrome" for 
associations of obesity, diabetes mellitus, hyperlipoproteinemia, 
hyperuricemia, and Hepatic steatosis when describing the additive 
effects of risk factors on atherosclerosis.43 
The same year, Singer used the term for associations of obesity, 
gout, diabetes mellitus, and hypertension with hyperlipoprotenemia.44  
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In 1988, in his Banting lecture, Gerald M. Reaven proposed 
insulin resistance as the underlying factor and named the constellation 
of abnormalities Syndrome X. Reaven did not include abdominal 
obesity, which has also been hypothesized as the underlying factor, as 
part of the condition.45  
 
RISK FACTORS 40 
¾ Overweight / Obesity 
¾ Sedentary Lifestyle 
¾ Stress 
¾ Aging  
¾ Diabetes Mellitus 
¾ Coronary Heart Disease 
¾ Lipodystrophy 
 
ETIOLOGY 
INSULIN RESISTANCE 
The most accepted and unifying hypothesis to describe the 
pathophysiology of the metabolic syndrome is insulin resistance, 
caused by an incompletely understood defect in insulin action. The 
onset of insulin resistance is heralded by postprandial 
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hyperinsulinemia, followed by fasting hyperinsulinemia and, 
ultimately, hyperglycemia. 
An early major contributor to the development of insulin 
resistance is an overabundance of circulating fatty acids. The 
inhibition of lipolysis in adipose tissue is the most sensitive pathway 
of insulin action. Thus, when insulin resistance develops, increased 
lipolysis produces more fatty acids, which further decrease the 
antilipolytic effect of insulin. Excessive fatty acids enhance substrate 
availability and create insulin resistance by modifying downstream 
signaling. Fatty acids impair insulin-mediated glucose uptake and 
accumulate as triglycerides in both skeletal and cardiac muscle, 
whereas increased glucose production and triglyceride accumulation 
are seen in liver.40 
 
Increased Waist Circumference 
Relative increases in visceral versus subcutaneous adipose 
tissue with increasing waist circumference in Asian Indians explains 
the greater prevalence of the syndrome in these populations. It is also 
possible that visceral fat is a marker for, but not the source of, excess 
postprandial FFAs in obesity.40 
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Dyslipidemia 
The major lipoprotein disturbances are hypertriglyceridemia & 
decrease in HDL. 
Hypertriglyceridemia is an excellent marker of the insulin-
resistant condition. 
With fasting serum triglycerides >2.0 mM (~180 mg/dL), there 
is almost always a predominance of small dense LDLs. Small dense 
LDLs are thought to be more atherogenic.40 
 
Glucose Intolerance 
The defects in insulin action lead to impaired suppression of 
glucose production by the liver and kidney and reduced glucose 
uptake and metabolism in insulin-sensitive tissues, i.e., muscle and 
adipose tissue.40  
 
Hypertension 
In the setting of insulin resistance, the vasodilatory effect of 
insulin is lost, but the renal effect on sodium reabsorption and increase 
in the activity of the sympathetic nervous system is preserved, which 
leads to hypertension.40  
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Proinflammatory Cytokines 
The increases in proinflammatory cytokines, including 
interleukin (IL) 1, IL-6, IL-18, resistin, tumor necrosis factor (TNF)  , 
and C-reactive protein (CRP), reflect overproduction by the expanded 
adipose tissue mass. Adipose tissue-derived macrophages may be the 
primary source of pro-inflammatory cytokines locally and in the 
systemic circulation.40 
 
Adiponectin 
Adiponectin is an anti-inflammatory cytokine produced 
exclusively by adipocytes. Adiponectin enhances insulin sensitivity 
and inhibits many steps in the inflammatory process. In the liver, 
adiponectin inhibits the expression of gluconeogenic enzymes and the 
rate of glucose production. In muscle, adiponectin increases glucose 
transport and enhances fatty acid oxidation, partially due to activation 
of AMP kinase. Adiponectin is reduced in the metabolic 
syndrome.46,47 
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In addition to the features specifically associated with metabolic 
syndrome, insulin resistance is accompanied by other metabolic 
alterations. These include increases in, 
( Uric acid48 
( apoB and C III, 
( prothrombotic factors (fibrinogen, plasminogen activator 
inhibitor 1), 
( serum viscosity,  
( asymmetric dimethylarginine,  
( homocysteine, 
( white blood cell count,  
( CRP, 
( microalbuminuria, 
( nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic 
steatohepatitis (NASH) 
( polycystic ovarian disease (PCOS), and 
( obstructive sleep apnea (OSA).40 
Diagnosis 
There are currently two major definitions for metabolic 
syndrome provided by the International Diabetes Federation and the 
revised National Cholesterol Education Program, respectively. 
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IDF 
The IDF consensus worldwide definition of the metabolic 
syndrome.49 
Central obesity (defined as waist circumference with ethnicity 
specific values), ≥ 90 cm in men and ≥ 80 cm in women for South 
Asian and Chinese people. 
 
AND any two of the following: 
Raised triglycerides : > 150 mg/dL (1.7 mmol/L), or specific treatment 
for this lipid abnormality. 
Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males, < 50 
mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid 
abnormality. 
Raised blood pressure : systolic BP > 130 or diastolic BP >85 mm Hg, 
or treatment of previously diagnosed hypertension. 
Raised fasting plasma glucose :(FPG)>100 mg/dL (5.6 mmol/L), or 
previously diagnosed type 2 diabetes.  
# If BMI is >30 kg/m², central obesity can be assumed and waist 
circumference does not need to be measured. 
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NCEP 
The US National Cholesterol Education Program Adult 
Treatment Panel III50 requires at least three of the following:  
Central obesity: waist circumference ≥ 102 cm or 40 inches (male),          
≥ 88 cm or 36 inches(female) 
Dyslipidaemia: TG ≥ 1.695 mmol/L (150 mg/dl) 
Dyslipidaemia: HDL-C < 40 mg/dL (male), < 50 mg/dL (female) 
blood pressure ≥ 130/85 mmHg 
Fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dl). 
The two differences are that IDF state if BMI>30 kg/m2 central 
obesity can be assumed and waist circumference does not need to be 
measured. However, this potentially excludes any subject without 
increased waist circumference if BMI<30, whereas, in the NCEP 
definition, metabolic syndrome can be diagnosed based on other 
criteria and the IDF uses geography-specific cut points for waist 
circumference, while NCEP uses only one set of cut points for waist 
circumference regardless of geography. These two definitions are 
much closer to each other than the original NCEP and WHO 
definitions. 
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CAUSES OF HYPERURICEMIA IN TYPE 2 
DIABETES MELLITUS PATIENTS  
 
1. DIETARY HABITS 
An increase in Serum urate level may occur in type 2 DM in 
various situations like Purine rich diet such as liver, anchovies, 
kidney, sardines, sweet breads, peas, cauliflower, brinjal and yeasts.40 
 
2. ALCOHOL 
 Alcohol increases serum urate level by accumulation of organic 
acids (betahydroxybutyrate, acetoacetate, lactate) that compete with  
urate for tubular secretion and accelerated breakdown of ATP by liver 
is increased (Beer contains high uric acid).40 
 
3. OBESITY 
 Various mechanisms play role in increase in serum urate by 
obesity, like anabolic effects of tissues because of Insulin resistance, 
increase in denovo biosynthesis of Purines, decreased excretion and 
increased breakdown.40 
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4. DEHYDRATION 
 Dehydration can impair uric acid excretion by decreased 
filtration and secretion and sometimes with acidosis by competition of 
H+ ion for excretion. Starvation again causes accumulation of organic 
acids that compete for the excretion of urate for tubular secretion.40 
 
5. SYSTEMIC HYPERTENSION 
 There are various studies regarding association of systemic 
hypertension with the elevated uric acid level. Probable mechanism 
suggested is impaired excretion of urate because of intrinsic renal 
defect in hypertension.40 
 
6. LACTIC ACIDOSIS AND DIABETIC KETOACIDOSIS 
 Dehydration and Pre renal azotemia both can impair filtration 
and secretion of urate leading to retention and also these may cause 
diminished reabsorption of uric acid. Again in the setting of acidosis 
H+ ion compete with uric acid leading to enhanced reabsorption and 
retention.40 
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7. HYPERGLYCEMIA 
 Both uric acid and glucose levels are positively related to body 
mass index. The association of uric acid in relation to glucose reflects 
the biochemical interaction between serum glucose metabolism and 
purine metabolism.40 
 
8. RENAL INSUFFICIENCY 
 Decreased urate filtration contributes to the hyperuricemia of 
renal insufficiency. But the correlation between BUN, Serum 
creatinine and serum uric acid concentration per unit of GFR increases 
progressively with renal insufficiency. The tubular secretory capacity 
tends to be preserved, the tubular reabsorbtive capacity is decreased 
and extra renal clearance of uric acid increases as the renal damage 
becomes more severe.40 
 
9. DRUGS 
 They mainly act by competitive inhibition of uric acid 
excretion. Salicylates and nicotinic acid directly compete with the 
urate for tubular secretion. Diuretics, L-dopa, Pyrazinamide, 
Ethambutol, cyclosporine decreases the secretion of urate in the 
tubules.40 
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URIC ACID AND INSULIN RESISTANCE 
 Nearly 120 years have elapsed since uric acid was first 
described as a potential factor in the development of cardiovascular 
disease.3 The actual mechanism of hyperuricemia found in many 
diabetic patients is not known, but different theories have been 
presented. 
 
 Quinones et al observed that hyperuricemia is a frequent finding 
in Insulin resistant states. He found that insulin induces changes in 
fractional uric acid and sodium excretion co-related with one another 
and physiological hyperinsulinemia acutely reduces urinary uric acid 
and sodium excretion in coupled patients. They also observed that in 
Insulin resistant individuals compensatory hyperinsulinemia imposes a 
chronic antinatriuretic and anti uricosuric pressure on the kidney.51 
 
 Moriwaki et al studied the effects of glucose infusion on the 
renal clearance of uric acid, xanthine and oxypurinol and found that 
the effect was not related to osmotic diuresis, but induced by 
glycosuria and  hyperglycemia.52 
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 Muscilli et al observed that effect of insulin or urinary excretion 
in normal subjects and found that hyperinsulinemia caused a 
significant decrease in the urinary excretion of uric acid.53 
 
 Tkac et al found that higher mean serum uric acid level in 
myocardial infarction group was associated with increasing age and 
serum creatinine levels. It was associated with elevated TGL, BMI and 
hypertension.54 
 
 Woo et al study results found positive association between 
serum uric acid concentration and BMI, with systolic and diastolic BP, 
urea, creatinine, fasting glucose 2 hour insulin, TGL, apolipoprotein B 
in men. Similar but fewer associations were seen in women with 
additional positive associations with age. The study suggests that 
serum uric acid may be a Marker for the presence of an adverse 
cardiovascular risk profile.55 
 
 Wannamethee et al conducted in their study that serum uric acid 
is not a truly independent risk factor for coronary acting disease. 
Increased serum uric acid appears to be an integral part of the cluster 
of risk factors associated with the insulin resistance syndrome that 
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include central obesity, increased TG level and serum cholesterol 
level.56 
 
 Pearl et al study concluded high molar equivalent serum anti 
oxidant capacity (MESA) between diabetics and non-diabetics showed 
uric acid as a free radical scavenger is NIDDM.57 
 
 There are certain clinical clustering groups with increased 
cardiovascular risk, which have associated hyperuricemia.58 They are, 
1. African American patient group. 
2. Patients group with excessive alcohol consumption. 
3. Hypertensive patient groups 
4. Non diabetic patient groups with acclerated atherosclerosis.  
5. Congestive heart failure patients group with ischemic 
cardiomyopathy.  
6. Metabolic syndrome patients group   
7. Renal disease patients group and  
8. Patients group taking diuretics. 
 
Each of the clustering group has metabolic mechanism that may 
help to explain why serum uric acid may be elevated.  
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MECHANISM: 
 Type 2 Diabetics mellitus is strongly associated with 
hyperuricemia.59 
 Potential mechanism involved in the association of 
hyperuricemia and type 2 Diabetes mellitus include the following: 
 
1. Altered renal sodium handling causes decreases renal blood 
flow and diminishes uric acid excretion.60 
2. Decreased GFR stimulating urate absorption.61 
3. Microvascular disease resulting in local tissue ischemia. 
4. Ischemia associated with increased lactate production. 
5. Ischemia induces increased xanthine oxidase production.61  
 
Other factors which may contribute are alcohol abuse, lead 
intake, obesity, insulin resistance and diuretic use. 
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Mechanism of Hyperuricemia in Hyperinsulinemia61 
Hyperinsulinemia 
↓ 
Altered renal sodium handling 
↓ 
↑Arterial pressure 
↓Renal blood flow 
↓Uric acid excretion 
↓ 
Hyperuricemia 
 
 Increased serum uric acid has been found to predict the 
development of renal insufficiency in individuals with normal 
function.  
 In type 2 Diabetes mellitus hyperuricemia seems to be 
associated with metabolic syndrome and with early onset or increased 
progression to overt nephropathy. 
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From the review the following conclusion was arrived: 
 Determining the truth in medical science is a difficult business. 
Serum uric acid may or may not be an independent risk factor because 
its linkage to other risk factors is so strong. However there is not much 
correlation regarding its role as a marker or risk factor that is clinically 
significant and relevant. 
 
 Hyperuricemia should alert the clinician to an overall increased 
risk of Cardiovascular disease. Elevation of uric acid > 4 mg/dl should 
be considered a “Red Flag” in those patients at risk for cardiovascular 
diseases and should alert the clinician to strive and utilize a global risk 
reduction programme to reduce the complications of atherogenic 
process.58 
         Hayden and Tyagi et al have suggested the RAAS protocol for 
these patients to reduce the atherogenic process58 
          R –  Reductase inhibitors ( HMG Co-A ) 
          A – ACE inhibitors, ARB 
                 Aspirin 
                 Adrenergic blockade 
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          A - Aggressive control of diabetes 
                Aggressive control of B.P (losartan)3 
                Aggressive control of uric acid (allopurinol) 
          S – Life Style 
                 Stop Smoking 
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DEFINITIONS USED IN PRESENT STUDY 
 
1. DIABETES MELLITUS: 
 Criteria for the diagnosis of diabetes mellitus (modified form of 
American Diabetes Association, 2003) 
1. Symptoms  of diabetes + (R) blood glucose ≥ 200 mg/dl. 
2. Fasting plasma glucose ≥ 126 mg/dl. 
3. Two hour plasma glucose (Post prandial) ≥ 200mg/dl during 
an oral glucose tolerance test.  
 
2. HYPERURICEMIA: 
 Hyperuricemia is defined as serum uric acid level ≥ 8mg/dl in 
males and ≥ 6 mg/dl in females.  
 
3.  BODY MASS INDEX: 
 It is estimated by using the formula : weight (kg)/ Height2(m) 
 
4. OBESITY: 
 Obesity is usually defined as body mass index > 30, body mass 
index between 25-30 kg/m2 as overweight. Body mass index between 
25-30 should be viewed as medically significant, especially in the 
presence of other risk factors like hypertension, diabetes.  
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 Large scale epidemiological studies suggest that cardiovascular 
morbidity begins to rise when body mass index ≥ 25, suggesting that 
the cut of for obesity should be lowered.  
 
WAIST HIP RATIO: 
 The  waist is measured by taking a circumference that gives the 
narrowest measurement between the rib cage and the iliac crest. The 
hip measurement is taken by measuring at a level that gives the 
maximal measurement of hip over the buttocks. It is a simple, and 
convenient measurement that is unrelated  to height, correlates closely 
with body mass index and waist hip ratio is an approximate index of 
intra abdominal  fat mass and total body fat. 
 Waist hip ratio > 0.8 in women and > 1.0 in men being 
abnormal.  
 
LIPID PROFILE ABNORMALITY 
 According to NCEP-ATP III guidelines, the following lipid 
values were considered as abnormal.  
 Triglycerides >150 mg/dl  
HDL < 40 mg/dl (Male) and < 50 mg/dl (female). 
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MATERIALS AND METHODS 
 
SETTING : Government Mohan Kumaramangalam 
Medical college, Salem-30. 
COLLABORATIVE 
 
: Department of Biochemistry,  
Government Mohan Kumaramangalam 
Medical college, Salem-30. 
STUDY DESIGN : Descriptive analytical study 
PERIOD OF STUDY : February 2008 to September 2009 
SAMPLE SIZE : 70 Cases. 
ETHICAL COMMITTEE 
APPROVAL 
: The present project was approved by 
the Ethical committee. 
 
INCLUSION CRITERIA: 
1. Patients with type 2 diabetes mellitus (patients were taken 
irrespective of their glycemic control and their duration of 
diabetes). 
2. Patients who were above 40 years were included. 
3. Both sexes were included. 
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EXCLUSION CRITERIA: 
1. Patients with renal failure. 
2. Pregnancy & lactating mothers. 
3. Patients who were on long term diuretics & steroid. 
4. Patients who were regularly consuming alcohol. 
5. Patients who were on anti metabolite and chemotherapy 
drugs. 
6. Patients who had hepatic & metabolic disorders. 
7. Patients who had PVD/CVA/ Pulmonary Tuberculosis.  
8. Renal transplant patients. 
 
CONTROLS: 
 Subjects who were above 40 years and had normal blood sugar 
and who met the above exclusion criteria. 
 
CONSENT: 
 The study group thus identified by the above criteria (inclusion 
and exclusion) were first instructed about the nature of study. Willing 
participants were taken up after getting a written informed consent 
from them.  
 
  38
MATERIALS: 
 Thus a total of 70 cases who satisfied the inclusion and 
exclusion criteria above were taken up for subsequent study. 30 age 
and sex matched  subjects were kept as control. 
 
CONFLICT OF INTEREST: 
 There was no conflict of interest. 
 
FINANCIAL SUPPORT: 
  Nil. 
 
LIMITATIONS: 
 1. Because of limited resources GTT, HbA1C, leptin level, C 
peptide assay, plasma insulin assay could not be tested. 
 2. X ray chest was not performed is every case due to technical 
limitation.  
 3. Only serum uric acid levels were analysed. Urinary excretion 
and urate clearance was not done.  
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METHODS: 
 Selected socio- demographic, clinical, laboratory data were 
elicited from the patients and controls and recorded in proforma. 
1. Socio demographic data. 
• Age 
• Sex 
2. Clinical Data. 
• Body weight  
• Height  
• BMI, waist hip ratio (WHR) 
• Systolic / Diastolic blood pressure 
• Cardiovascular risk factors 
• Clinical examination 
 
3.  Laboratory Data: 
• Blood urea estimation was done manually by using diacetyl 
monoxime method (DAM). 
• Serum creatinine estimation was done by using COBAS auto 
analyser. 
• Serum uric acid was done by using semi auto analyser. 
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PRINCIPLE: 
 Uric acid is converted by uricase to allantoin and hydrogen 
peroxide in the presence of peroxidase (POD) which oxidizes the 
chromogen to a red coloured compound which is read at 500mm.65 
Uric acid + 2H2O + O2 Allantion + CO2+H2O2
URICASE
 
Red quinolone + H2O +HCl (DHBS 
3,5 dicholoro-2 hydroxy benzene 
sulphonic acid)
DHBS POD
2H2O2 + 4 Aminopyrine +
 
STATISTICAL ANALYSIS: 
 Data was entered in Microsoft excel spread sheet and analysed 
statistically using standard statistical software. Student ‘t’ values was 
applied for significance. Significance of ‘P’ value was below 0.05. 
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RESULTS 
 
 The total number of subjects included in this study was 100. 
Among those 100 subjects, 70 were cases (type 2 diabetes mellitus) 
and 30 were controls (non diabetic). 
 
Table – 1 : Introduction 
 CASES CONTROLS 
Total No. 70 30 
Gender M=43;F=27 M=18; F=12 
Age (Years) 43 to 72 41 to 75 
Mean age (Years) 59.13 56.97 
BMI 19.6-29.4 18.4-26.0 
WHR 0.73-1.14 0.76-1.12 
FBS (mg/dl) 105-172 86-120 
PPBS (mg/dl) 157-302 139-181 
SUA (mg/dl) 2.8-8.3 2.9-5.3 
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ANALYSIS OF CASES AND CONTROL WITH RESPECT TO 
AGE: 
 The age of the subjects in the study group ranged from 43 to 72 
years. The mean and standard deviation for age of the cases and 
controls were 59.13±9.11 and 56.97±8.41 respectively, there was no 
significant difference among the cases and controls with reference to 
the age. The distribution of cases and controls in relation to age is 
provided in table 2 given below. 
 
Table 2 : Cases and Controls in relation to age 
Age Group 
Cases Controls 
No % No % 
40-50 14 20 6 20 
51-60 21 30 10 33.33 
61-70 26 37.14 11 36.66 
71-80 9 12.85 3 10 
Mean 59.13 56.97 
S.D. 9.11 8.41 
 
P = 0.0551 (Not Significant) 
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ANALYSIS OF CASES AND CONTROLS WITH RESPECT TO 
GENDER 
 Among 70 cases studied, there were 43 males and 27 females, 
among 30 controls there were 18 males and 12 females. The details 
are given in table 3 provided below. 
 
Table 3 : Cases and Controls in relation to gender 
Sex 
Cases Controls 
No % No % 
Male 43 61.43 18 60 
Female 27 38.57 12 40 
Total 70 100 30 100 
P = 0.7901 (Not significant) 
 
 The sex composition of the study group and control group does 
not differ. 
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ANALYSIS OF CASES AND CONTROL WITH RESPECT TO 
BMI: 
 Among 70 cases and 30 controls screened for BMI, none were 
obese. The mean and standard deviation for BMI of cases and controls 
were 24.93 ± 3.13 and 21.8 ± 2.3 respectively. The details are shown 
in Table 4 given below: 
 
Table 4 : Cases and Controls in relation to BMI 
BMI 
Cases Controls 
No % No % 
< 25 34 48.57 24 80 
 ≥ 25 36 51.42          6 20 
Total 70 100 30 100 
Mean 24.93 21.8 
S.D. 3.13 2.3 
 
P = 0.0002 (Significant) 
 
 The BMI of the study group was significantly higher than that 
of control group. 
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BLOOD SUGAR DISTRIBUTION AMONG CASES 
 The details of fasting and post prandial blood sugar distribution 
among the cases are shown in table 5 given below: 
 
Table 5 : (F) BS and (PP) BS among cases 
BL. Sugar Mean S.D. 
F (BS) 132.79 36.72 
PP (BS) 206.2 37.49 
 
 The mean and standard deviation for fasting blood sugar was 
132.79±36.72 similarly for post prandial blood sugar was  
206.02 ± 37.49 among diabetes. Thus showing their diabetic status 
was under  the control. 
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DISTRIBUTION OF CASES AND CONTROLS IN RELATION 
TO SELECTED CARDIOVASCULAR RISK FACTORS 
 Analysis of cases and controls in relation to selected 
cardiovascular risk factors are provided in Table 6 given below. 
Table 6 : Selected Cardiovascular Risk Factors 
Risk Factor 
Cases Controls 
No % No % 
Family History 
Yes* 20 28.57 7 23.34 
No 50 71.43 23 76.66 
* P value 0.5622 (Not Significant) 
Smoking among Males 
Yes** 19 27.14 8 26.66 
No 51 72.85 22 73.33 
** P value 0.5746 (Not Significant) 
Hypertension 
Yes*** 18 25.71 7 23.33 
No 52 74.27 23 76.67 
*** P value 0.5044 (Not Significant) 
 
 There was no significant difference between cases and controls 
in relation to selected cardiovascular risk factors. 
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DISTRIBUTION OF CASES AND CONTROLS IN RELATION 
TO SERUM URIC ACID LEVEL (SUA): 
 Serum uric acid in the study population and control varied from 
2.8 to 8.3 and 2.9 to 5.3 mg/dl respectively. The mean and standard 
deviation of uric acid among cases was 5.25 ± 1.59 while in control it 
was 3.91 ± 0.98 respectively. 
 The details are shown in the table 7 given below. 
 
Table 7 : Serum Uric Acid level in diabetics and controls 
Serum Uric 
Acid * 
Cases Controls 
Mean S.D. Mean S.D. 
5.25 1.59 3.91 0.98 
* P value : 0.0001 (significant) 
 
 The serum uric acid level of diabetics was very much elevated 
compared with controls and it was highly significant. 
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Fig : 3 – Mean Serum Uric Acid levels in cases and controls 
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ANALYSIS OF HYPERURICEMIA IN CASES AND 
CONTROLS 
 Hyperuricemia is defined as SUA level ≥ 8 mg/dl in males and 
≥6 mg/dl in females. 15 cases had hyperuricemia while none in 
controls. The results are displayed in table 8 given below: 
 
Table 8 : Hyperuricemia in Cases and Controls 
Hyperuricemia 
Cases Controls 
No % Mean S.D No % Mean S.D 
+ 15 21.4 7.16 0.5 0 - - - 
- 55 78.67 4.73 1.21 30 100% 3.91 0.98
 
*P = 0.0001 (Significant) 
 This table clearly shows that the prevalence of hyperuricemia is 
more  in diabetic patients when compared to controls. 
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Fig. 4 : Hyperuricemia in Cases and Controls 
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ANALYSIS OF GENDER DISTRIBUTION WITH SERUM 
URIC ACID AMONG THE CASES 
 The mean value of serum uric acid was 5.06 ± 1.64 in males and 
5.63 ± 1.12 in females and details are given in table 9 below. 
 
Table 9 : Serum Uric Acid values in relation to gender among 
cases 
Sex No Mean S.D. P Value 
Male 43 5.06 1.64 
0.0196 
Female* 27 5.93 1.12 
 
*P Value = 0.0196 (Significant) 
  
In the study group mean uric acid values were higher in females 
than males and the difference was statistically significant. 
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SERUM URIC ACID VALUE IN RELATION TO BMI IN 
CASES 
 The mean value of serum uric acid was 6.13 ± 1.45 in those 
with BMI > 25. It was significantly higher than compared to those 
having  BMI < 25. The mean value of serum uric acid in BMI < 25 
was 4.13±1.23.  
 The details are shown in table 10 given below: 
 
Table 10 : Uric Acid with regard to BMI among cases 
BMI No. Mean S.D. 
< 25 34 4.13 1.23 
> 25* 36 6.13 1.45 
 
* P Value = 0.0001 (Significant) 
 Mean uric acid level was positively correlated with BMI. 
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Fig. 5 : SERUM URIC ACID VALUE IN RELATION TO BMI 
IN CASES 
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SERUM URIC ACID VALUE IN RELATION TO WAIST HIP 
RATIO (WHR) 
 Uric acid level increases with increased WHR. The WHR 
abnormality was considered in 33 cases based on, WHR above 1.0 for 
men, above 0.8 for women and correlated with uric acid level was 
significant details are shown in table 11 given below:  
 
Table 11 : Waist Hip Ratio and Hyperuricemia 
WHR 
Abnormality No. Mean S.D. 
Yes* 33 5.93 1.37 
No 37 4.63 1.3 
 
* P Value = 0.0001 (Significant) 
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Fig 6 : Waist Hip Ratio and Hyperuricemia 
 
 
4.63
5.93
0
1
2
3
4
5
6
7
Absent Present
WHR Abnormality
M
ea
n 
Se
ru
m
 U
ric
 A
ci
d
 
 
  56
 
SMOKING AND SERUM URIC ACID AMONG THE CASES 
(ONLY IN MALES) 
 The mean value of serum uric acid among smokers was 
5.03±1.69 when compared to non smokers 5.32±1.42, but the 
difference was not significant statistically, this is shown in table 12 
given below: 
 
Table 12 : Uric Acid Values in relation to Smoking (only in males) 
Smoking No. Mean S.D. 
Yes* 19 5.03 1.69 
No 51 5.32 1.42 
 
* P Value = 1.5472 (Not Significant) 
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SERUM URIC ACID VALUES IN HYPERTENSIVE PATIENTS 
 The mean serum uric acid level in the hypertensive group 
(6.45±1.15) was significant more than non hypertensive group 
(4.83±1.43) in the cases and the results are shown in the table 13 given 
below: 
 
Table 13 : Serum Uric Acid values in relation to Hypertension 
HT No. Mean S.D. 
Yes* 18 6.45 1.15 
No 52 4.83 1.43 
 
* P Value = 0.0001 (Significant) 
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SERUM URIC ACID LEVEL IN RELATION TO LIPID 
PROFILE ABNORMALITY 
 The mean serum uric acid level in patients with lipid profile 
abnormality was 6.67±0.94, while it was 4.75±1.44 in patients without 
lipid profile abnormality and it was highly significant. The results are 
shown in table 14 given below: 
 
Table 14 : Serum Uric Acid value in relation to lipid profile 
abnormality 
Lipid Profile 
Abnormality No. Mean S.D. 
Yes* 18 6.67 0.94 
No 52 4.75 1.44 
 
* P Value = 0.001 (Significant) 
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Table 15 : CAD and Hyperuricemia 
Type of 
CAD 
No. of 
Patients 
Total no. of 
Hyperuricemia Sex % 
Ischaemia 16 4 2M + 2F 25% 
Infarction 8 4 1M + 3F 50% 
 
 This table was showing number of patients with Ischaemia – 16. 
Of these only 4 had hyperuricemia with equal sex distribution (1:1). 
 
 Number of patients with infarction was 8. Of these only 4 had 
hyperuricemia, one male and three female patients (1:3). 
 
 Percentage of hyperuricemia in infarction is higher than in 
ischaemia, and female patients were more involved in CAD than 
males  in relation to hyperuricemia. 
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SERUM URIC ACID VALUE IN RELATION TO DURATION 
OF DIABETES 
 Mean value of Serum uric acid level was higher in longer 
duration (9-12 years) of diabetes 6.87±1.03, when compared to shorter 
duration (2-4 years) of diabetes 4.31±1.08. This is shown in table 16 
given below:  
 
Table 16 : Duration of Diabetes and Hyperuricemia 
DOD No. Mean S.D. 
2-4 years 12 4.31 1.08 
5-8 years 37 5.01 1.891 
9-12 years* 21 6.87 1.03 
 
* P Value = 0.001 (Significant) 
 Uric acid level increases with increasing duration of diabetes 
and it was statistically significant. 
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Fig 7 : Duration of Diabetes and Hyperuricemia 
 
 
4.31
5.01
6.87
0
1
2
3
4
5
6
7
M
ea
n 
U
ric
 A
ci
d
2-4 years 5-8 years 9-12 years*
Mean Serum Uric Acid
 
  62
DISCUSSION 
 
 Diabetes is the most common risk factor for cardiovascular 
disease, and it is present in nearly 25% adults and increases in 
prevalence with age.2 
 
 Hyperuricemia is one of the components of metabolic 
syndrome. “In the absence of gout the presence of hyperuricemia in 
patients with type 2 diabetes mellitus is an important marker as well as 
an added risk factor for atherosclerosis.”7 
 
 In this study the relation between serum uric acid level and 
diabetes was examined. Uric acid is a marker for CAD in combination 
with other risk factors among diabetics. 
 
 Though uric acid level and age was independent it is possible 
that duration of the illness may have an impact on uric acid levels. 
 
 In the present study females have higher uric acid level when 
compared to males. The mean uric acid value in males was 5.06±1.64 
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while in females it was 5.93±1.13, and the difference was statistically 
significant in this study. The possible reasons for such difference may 
be attributable to increased BMI and increased WHR among women. 
 
 In the present study serum uric acid correlated well with body 
mass index (BMI). The mean uric acid in those subjects with BMI > 
25 was higher than those with BMI < 25 (6.13±1.45 Vs 4.13±1.23) 
and the difference was statistically significant. 
 
 Rathmann et al., assessed the various components of insulin 
resistance syndrome in young black and white adults. They concluded 
that body mass index showed strongest positive correlation with the 
uric acid among insulin resistant components.62 
 
 Waist hip ratio is an important measure of obesity, especially 
central obesity. Intrabdominal fat has significant implication for 
morbidity than subcutaneous fat present in buttocks and extremities.40 
 
 Abdominal obesity is a component of metabolic syndrome. 
Waist circumference > 102 cm in men and >88cm in women is 
  64
abnormal. In this study patient with higher waist hip ratio had higher 
uric acid level when compared with low waist hip ratio. 
 
 The mean uric acid value in patients with waist hip ratio 
abnormality and patients without waist hip ratio was 5.93±1.38 and 
4.63±1.3 respectively and the difference was statistically significant. 
 
 Strong epidemiologic data have linked serum uric acid to 
hypertension in humans and experimental animal data suggests 
hyperuricemia causes hypertension.63,64 The Olivetti heart study had 
shown a independent positive association between serum uric acid and 
development of hypertension. 
 
 When the level of serum uric acid in hypertensive patients was 
compared with non-hypertensive patients in cases, the difference was 
significantly higher in the present study.(6.45±1.15 vs 4.83±1.43) 
 
 Elevated triglycerides is the most important risk factor in 
acceleration of atherosclerosis. There is a significant relationship 
between serum uric acid and dyslipidemia. In the present study 
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dyslipidemia was noticed as a risk factor in those with CAD, who had 
significantly elevated serum uric acid levels. (6.67±0.94 vs 4.75±1.44) 
 
 “Uric acid stabilizes the platelet aggregation and enhances 
thrombotic tendency,” thus suggesting hyperuricemia as a strong 
predictor of myocardial infarction and stroke.66 
 
 Patients with Poor metabolic control and longer duration of 
diabetes were more susceptible to develop various complications 
including hyperuricemia.67 Our study also shows that higher level of 
serum uric acid was seen in patients with longer duration of diabetes 
when compared with shorter duration of diabetes, 6.87±1.03  
(9-12yrs) vs 4.31±1.08 (2-4yrs) This difference was statistically 
significant. 
 
 Uric acid >4 mg/dl should be considered as a “Red flag” in 
those patients at risk for cardiovascular disease.58 In this study 78.57% 
of diabetic patients have serum uric acid level >4 mg/dl, while only 
30% of the control have serum uric acid >4mg/dl. In these patients the 
clinician should strive to utilize global risk reduction programme to 
reduce the complications of atherogenic process. The details in 
relation to this study is shown in the table 17 given below: 
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Table 17 : Cases and Controls in relation to Uric acid 
Serum Uric 
Acid 
Cases Controls 
No % No % 
< 4 mg. 15 21.43 21 70 
> 4mg. 55 78.57 9 30 
 
P = 0.0001 (Significant) 
 
Fig. 8 : Cases and Controls in relation to Uric acid 
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 The association of serum uric acid with cardiovascular disease 
has been appreciated for nearly half a century. However, its role as a 
cardiovascular risk factor remains controversial.68 In an epidemiologic 
follow up study an association between serum uric acid and 
cardiovascular disease was shown. The PIUMA study69 also 
concluded that raised serum uric acid is a powerful risk marker for 
subsequent cardiovascular disease and all cause mortality. 
 
 Of the 70 cases of type 2 diabetes mellitus, hyperuricemia was 
observed in 15 patients which accounts for 21.43% of cases. Canon70 
showed a prevalence of hyperuricemia in 25% of longstanding 
uncontrolled diabetes. But in this study many of the cases were on 
treatment which might have affected the results. 
 
 A large body of evidence links uric acid with metabolic 
syndrome of insulin resistance, obesity, hypertension and 
dyslipidemia. In this study relationship between obesity, hypertension, 
dyslipidemia and hyperuricemia was statistically significant. 
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CONCLUSION 
 
¾ Uric acid was significantly elevated in diabetic population. 
¾ The serum uric acid level was independent of age and smoking 
status in males. 
¾ Significant correlation was noticed between serum uric acid and 
BMI as well as WHR. 
¾ Significant elevation of uric acid level was observed more 
among females. 
¾ Elevated uric acid levels were significantly noticed among those 
with hypertension, dyslipidemia, coronary artery disease and 
chronicity of the diabetes. 
¾ Uric acid level above 4 mg/dl in diabetic population (considered 
as a “Red flag” sign) was a marker or risk factor for CAD, 
which was present in 78% of study population. 
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SUMMARY 
 
 Diabetes mellitus is strongly associated with hyperuricemia. 
The role of uric acid as a independent risk factor for cardiovascular 
disease is a matter of controversy. The present study was proposed to 
assess the uric acid status in patients with diabetes mellitus and to find 
out its association with age, gender, BMI, WHR, smoking and CAD. 
With rigid criteria, patients were selected carefully and evaluated on 
social, clinical and laboratory aspects after getting institutional, ethical 
clearance and informed consent. 30 healthy age, sex matched 
individuals were kept as control. There were 43 males and 27 females 
in the study group and 18 males and 12 females in the control group.  
There was no significant difference among cases and controls in 
relation to age. 
 
 In study group, BMI below 25 was seen in 34 cases (48.57%), 
BMI above 25 seen in 36 cases (51.42%) which was significantly 
more than controls. BMI  had significantly correlated with 
hyperuricemia. Similarly WHR was greater among women than men 
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in diabetics, which also correlated with elevated serum uric acid 
significantly. 
 
 Elevated serum uric acid level was noticed more among those 
who had hypertension dyslipidemia, coronary artery disease and they 
were significant. Patients with longer duration of diabetes also had 
elevated uric acid level. 
 
 The factors contributing to hyperuricemia in diabetes are,  
1. Hyperinsulinemia acutely reduces urinary uric acid and sodium 
excretion. 
2. Hyperinsulinemia imposes a chronic antinatriuretic and anti 
uricosuric effect on the kidney. 
3. Microvascular disease in diabetes mellitus causes local tissue 
ischemia and decreased renal blood flow leading to ischemia 
with associated lactate production that blocks urate secretion in 
proximal tubules. Increased uric acid synthesis occurs due to 
increased purine metabolism, ischemia induced increased 
xanthine oxidase production, insulin resistance and diuretic use.  
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Routine annual estimation of uric acid among diabetics from the 
identification of diabetes will help the clinician to find out the 
changing trends of uric acid level which is likely to be influenced by 
control of blood sugar and development of hypertension, such cases 
should be carefully monitored for CAD as well as other vascular 
episodes. 
 
 Since uric acid is a confounding factor and multiple factors are 
involved for elevated uric acid. A meticulous control of blood sugar, 
hypertension, dyslipidemia among diabetics will bring down elevated 
uric acid level in diabetics. 
 
 Let us have a Moto of,  
  “Assess diabetics for risk factors; 
  Assist to control them and 
  Arrest the development of complications” 
 With the Pharmacological and non pharmacological means. 
 
CASES MASTER CHART 
S. 
No. 
Age 
(Yrs.) Sex DOD BMI WHR Smoking 
Family 
History 
of 
Diabetes 
Systemic 
Hyper 
Tension 
IHD BS (F) 
BS 
(PP) 
Renal 
Parameters 
USG 
Abd 
ECHO 
/ ECG 
Lipid Profile 
Abnormality 
Retino 
Pathy 
Nauro 
pathy 
Sr.Uric 
acid 
1 52 M 6 20.6 0.86 Y N N N 136 222 N N N N N N 4.2 
2 69 M 10 27.8 1.08 Y Y Y Y 122 203 N N MI Y Y N 8.1 
3 43 M 2 19.6 0.73 N N N N 123 186 N N N N N N 2.8 
4 55 M 5 20.2 0.80 N N N N 109 173 N N N N N N 3.8 
5 62 M 8 28.8 1.12 Y N N N 137 233 N N N N N N 3.0 
6 51 M 3 21.9 0.86 N Y N Y 119 173 N N MI N N N 4.6 
7 61 M 7 23.2 0.80 Y N N N 149 200 N N N N N N 3.5 
8 47 M 3 20.4 0.78 N Y N N 107 187 N N N N N N 3.7 
9 62 M 6 23.7 0.84 N N Y Y 158 253 N N I N Y N 4.8 
10 44 M 4 23.3 0.83 N N N N 172 192 N N N N N N 4.0 
11 71 F 12 27.7 0.91 N N Y N 105 202 N N MI Y Y Y 6.2 
12 59 F 8 27.3 0.89 N Y N Y 137 170 N N I N N N 5.3 
13 72 F 14 27.4 0.93 N N Y Y 135 223 N N I Y Y N 6.1 
14 53 F 5 21.4 0.80 N N N N 164 222 N N N N N N 5.8 
15 67 F 4 22.6 0.83 N N N N 121 275 N N N N N N 5.7 
16 72 M 10 27.8 0.97 Y N Y Y 153 192 N N I Y Y N 6.4 
17 60 F 8 28.1 0.94 N N N Y 112 271 N N MI N N N 7.9 
18 47 F 5 20.2 0.80 N N N N 117 175 N N N N N N 5.8 
19 55 F 7 24.8 0.84 N Y N N 123 157 N N N N N N 4.0 
20 66 F 10 28.3 0.92 N N N N 135 157 N N N Y Y N 5.8 
21 43 M 2 19.6 0.76 Y N N N 139 192 N N N N N N 3.8 
22 67 M 7 20.4 0.80 Y Y N Y 159 201 N N I N N N 4.6 
23 63 M 9 27.4 0.82 Y N N Y 151 243 N N I N N N 5.8 
24 72 F 12 27.2 0.92 N N Y N 119 231 N N N Y Y N 6.3 
25 59 M 10 27.4 1.14 Y Y Y Y 147 243 N N I N N N 8.1 
26 57 F 6 28.2 0.81 N N Y N 145 174 N N N N N N 4.6 
27 62 F 6 24.5 0.92 N N N N 127 126 N N N N N N 4.0 
28 63 M 7 27.4 1.02 Y Y Y Y 109 223 N N MI N N N 6.5 
29 60 F 10 27.3 1.12 N Y N N 133 211 N N N N Y N 6.1 
30 58 F 9 28.4 1.10 N N N Y 114 216 N N I Y N N 5.7 
31 61 M 7 22.3 0.80 Y N N N 152 247 N N N N N N 3.2 
32 63 M 8 27.2 0.84 N N Y N 120 196 N N N N N N 4.6 
33 69 M 10 27.4 1.02 N Y Y Y 107 176 N N I Y Y N 8.1 
34 65 M 6 24.7 0.99 Y N N N 112 181 N N N N N N 5.6 
35 53 M 7 22.3 0.84 N N N N 141 243 N N N N N N 5.0 
36 54 M 6 23.0 0.86 N N N N 143 251 N N N N N N 4.8 
37 67 F 12 28.6 1.08 N Y Y Y 139 233 N N I Y Y N 6.7 
38 63 M 7 27.0 1.02 N N N N 137 211 N N N N N N 8.2 
39 66 F 6 27.8 1.00 N Y N N 111 209 N N N N N N 5.4 
40 61 M 6 23.8 0.88 N N N N 142 231 N N N N N N 3.0 
41 62 M 6 20.8 0.80 Y N N N 117 199 N N N N N N 3.1 
42 72 M 10 27.8 0.92 N Y Y Y 121 201 N N I Y Y Y 6.7 
43 57 M 7 20.2 0.80 N N N N 106 192 N N N N N N 3.2 
44 44 M 4 20.0 0.80 N N N N 109 157 N N N N N N 2.8 
45 71 F 8 29.0 1.08 N N N Y 151 245 N N MI Y N Y 7.7 
46 54 M 7 27.4 0.92 N Y N N 149 211 N N N N N N 5.2 
47 63 M 7 27.8 0.88 N N N N 108 238 N N N Y N N 3.8 
48 57 M 6 20.1 0.80 N N N N 117 187 N N N N N N 3.6 
49 67 M 10 28.7 0.96 Y N N Y 138 147 N N MI N N N 6.6 
50 69 M 12 27.8 1.00 N N Y Y 161 191 N N I Y Y N 6.6 
51 59 M 9 21.3 0.78 N N N N 152 301 N N N N N N 4.6 
52 72 M 10 27.6 0.92 N Y Y N 145 203 N N N Y N Y 6.6 
53 48 M 3 23.2 0.82 Y N N Y 157 219 N N I N N N 4.2 
54 57 F 7 26.8 0.88 N N N N 144 200 N N N Y N N 4.8 
55 69 F 10 27.8 0.96 N Y N Y 133 231 N N I N Y N 2.9 
56 52 F 5 27.0 0.90 N N N N 138 203 N N N N N N 4.2 
57 48 F 6 21.2 0.80 N N Y N 146 180 N N N N N N 8.0 
58 47 M 5 20.6 0.78 Y N N N 142 302 N N N N N N 3.1 
59 62 M 7 27.4 1.07 N N N Y 150 251 N N I N N N 6.3 
60 55 M 3 23.2 0.92 Y N N N 109 178 N N N N N N 4.7 
61 65 M 8 27.8 1.02 N Y N N 115 203 N N N N Y N 6.0 
62 63 F 7 29.4 0.80 N N N Y 126 241 N N I N N N 4.2 
63 72 F 14 29.0 1.09 N Y Y N 152 199 N N N Y Y Y 6.1 
64 51 F 3 23.1 0.84 N N N N 132 173 N N N N N N 6.4 
65 50 F 6 21.4 0.87 N N N N 106 161 N N N N N Y 5.5 
66 44 M 3 19.6 0.78 Y N N N 119 172 N N N N N N 2.8 
67 49 F 3 20.1 0.81 N N N N 137 253 N N N N N N 5.9 
68 72 M 12 28.4 1.09 Y Y N N 139 171 N N N Y Y Y 8.3 
69 45 F 7 24.7 1.06 N N N N 151 189 N N N N N N 4.9 
70 49 M 12 29.0 1.08 N Y Y Y 140 177 N N MI N Y N 5.9 
 
 CONTROLS MASTER CHART 
S. 
No. 
Age 
(Yrs.) Sex DOD BMI WHR Smoking 
Family 
History 
of 
Diabetes 
Systemic 
Hyper 
Tension 
IHD BS (F) 
BS 
(PP) 
Renal 
Parameters 
USG 
Abd 
ECHO / 
ECG 
Lipid Profile 
Abnormality 
Retino 
Pathy 
Nauro 
pathy 
Sr.Uric 
acid 
1 54 M 6 20.6 0.83 Y Y N N 92 154 N N N N N N 3.7 
2 46 M 3 19.4 0.80 N N N N 78 142 N N N N N N 5.2 
3 61 M 8 20.3 0.81 N Y N N 106 148 N N N N N N 2.9 
4 64 M 10 25.4 0.84 N N Y N 110 147 N N N N N N 3.6 
5 41 F 2 18.6 0.78 N N N N 110 167 N N N N N N 3.6 
6 59 F 7 21.4 0.82 N N N N 120 172 N N N N N N 4.5 
7 67 M 8 22.4 1.10 Y Y Y N 112 161 N N N N N N 5.5 
8 52 M 3 20.6 0.81 Y N N N 118 147 N N N N N N 3.2 
9 63 M 8 24.7 0.88 N N N N 120 162 N N N N N N 3.7 
10 60 F 4 23.8 0.87 N N N N 116 139 N N N N N N 3.8 
11 55 F 3 25.7 0.80 N N Y N 86 168 N N N N N N 4.3 
12 49 F 3 19.6 0.78 N N N N 92 167 N N N N N N 5.2 
13 44 M 3 18.4 0.82 Y N N N 118 149 N N N N N N 3.8 
14 55 M 6 20.4 0.83 N N N N 112 160 N N N N N N 3.2 
15 57 M 7 21.2 0.84 Y N N N 113 163 N N N N N N 4.9 
16 62 M 5 26.0 1.02 N Y N N 116 172 N N N N N N 1.3 
17 67 F 7 25.3 0.90 N N Y N 106 180 N N N N N N 3.9 
18 49 F 23 20.6 0.84 N N N N 112 142 N N N N N N 3 
19 51 F 3 21.4 0.86 N N N N 119 167 N N N N N N 3.7 
20 55 M 3 20.8 0.80 N Y Y N 106 143 N N N N N N 4 
21 66 F 10 25.8 0.87 N N N N 111 168 N N N N N N 3.4 
22 62 M 9 23.2 0.83 N N N N 107 167 N N N N N N 3.6 
23 64 M 8 25.6 0.82 Y Y N N 120 148 N N N N N N 3.8 
24 47 M 2 20.0 0.84 N Y N N 110 151 N N N N N N 3.7 
25 53 F 6 19.6 0.76 N N N N 105 170 N N N N N N 3.3 
26 64 F 5 20.3 0.80 N N N N 96 164 N N N N N N 3.1 
27 73 M 2 20.4 0.81 Y N Y N 98 170 N N N N N N 5.2 
28 74 M 2 19.6 0.80 N N N N 102 181 N N N N N N 5.1 
29 63 F 7 18.4 0.80 N N N N 100 176 N N N N N N 3.1 
30 75 M 8 25.6 1.08 Y N Y N 120 170 N N N N N N 3.4 
 
